Share This Page
Drug Price Trends for TLANDO
✉ Email this page to a colleague
Average Pharmacy Cost for TLANDO
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TLANDO 112.5 MG CAPSULE | 54436-0112-20 | 6.82323 | EACH | 2024-12-23 |
| TLANDO 112.5 MG CAPSULE | 74676-0112-02 | 6.82323 | EACH | 2024-12-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for TLANDO
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
|---|---|---|---|---|---|---|---|---|
| TLANDO 112.5MG CAP | Verity Pharmaceuticals Inc. | 54436-0112-20 | 120 | 556.99 | 4.64158 | EACH | 2024-03-05 - 2026-11-30 | Big4 |
| TLANDO 112.5MG CAP | Verity Pharmaceuticals Inc. | 54436-0112-20 | 120 | 672.65 | 5.60542 | EACH | 2024-03-05 - 2026-11-30 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
Market Analysis and Price Projections for Tlando
Introduction
Tlando (testosterone Oromucosal Gel) is a prescription hormone therapy indicated for testosterone replacement therapy (TRT) in adult males with hypogonadism. As a relatively new entrant into the testosterone replacement market, Tlando’s commercial trajectory depends on factors including market demand, competitive landscape, regulatory environment, and pricing strategies. This comprehensive analysis explores current market dynamics and projects the potential pricing evolution for Tlando over the upcoming years.
Market Overview: Testosterone Replacement Therapy Landscape
The global testosterone replacement therapy market has experienced steady growth, driven by increasing awareness of hypogonadism, aging male populations, and broader acceptance of hormone therapies. The market was valued at approximately $1.4 billion in 2022 and is projected to reach over $2 billion by 2027, with a compound annual growth rate (CAGR) of around 8% (Market Research Future, 2022)[1].
Key Market Segments include:
- Topical gels and patches: The dominant modality due to ease of use.
- Injectable formulations: Preferred for their potency and longer duration.
- Pellets and buccal formulations: Niche but growing segments.
- Oromucosal gels: Representing innovative delivery, like Tlando.
The increasing prevalence of hypogonadism, compounded by rising awareness and diagnosis, fuels demand. Additionally, safety and efficacy improvements, coupled with patient preferences for non-invasive administration, shape market growth.
Positioning of Tlando in the Market
Tlando is positioned as an oromucosal gel offering a distinctive delivery mechanism compared to traditional topical gels or injections. Its key selling points include:
- Rapid absorption: Provides flexible dosing.
- Reduced skin contact risks: Unlike topical gels.
- Potential for improved compliance: Due to unique administration.
Tlando's approval process by the FDA in 2021 marked a significant milestone, as it is among the few oromucosal testosterone products available in the US market, with a similar presence in select international markets.
Competitive Landscape
The market’s main competitors include:
- AndroGel (AbbVie): The market leader, with a market share of approximately 55%.
- Testim (Supernus): Another prominent topical gel.
- Axiron (Eli Lilly): Transdermal solution.
- Testosterone injections: Such as Depo-Testosterone (Pfizer).
- Other emerging formulations: Including pellets and novel delivery systems.
Tlando’s competitive advantage hinges upon differentiating dosing convenience, safety profile, and patient preference.
Regulatory and Reimbursement Environment
Regulatory approval from agencies like the FDA paves the way for commercialization but involves navigating reimbursement hurdles. Insurance coverage and formulary inclusion significantly influence market penetration.
Tlando’s pricing and presentation in relation to existing products determine reimbursement rates and patient access. High out-of-pocket costs might limit adoption, especially within price-sensitive segments.
Market Penetration and Adoption Trends
Initial rollouts typically focus on:
- Specialty clinics: Endocrinologists predominantly prescribe TRT.
- Physician education: Emphasizing Tlando’s benefits.
- Patient acceptance: Influenced by ease of use and side effect profile.
Adoption rates historically lag initial approval due to prescriber familiarity and formulary coverage, but early indications suggest increased uptake as awareness grows.
Price Analysis and Projections
Current Pricing Landscape
The average weekly price of testosterone gels in the US ranges from $150 to $250, depending on formulation and manufacturer. For example:
- AndroGel 1.62%: Approximately $230/week.
- Testim: Around $210/week.
- Axiron: Roughly $200/week.
Tlando is initially priced within this competitive range, around $180 to $210 per week, aligning with other oromucosal formulations.
Pricing Factors Influencing Tlando’s Price
- Manufacturing costs: Oromucosal delivery may involve higher production complexity.
- Market positioning: Competitive pricing to ensure uptake.
- Reimbursement negotiations: Insurers influencing net prices.
- Patient out-of-pocket costs: Affecting patient adoption and adherence.
Future Price Trajectory
Based on industry trends, certain factors could influence Tlando’s pricing over the next five years:
- Market saturation and competition: To maintain market share, price adjustments may be necessary.
- Manufacturing efficiencies: Economies of scale could lower costs and prices.
- Reimbursement landscape: Tighter negotiations favoring lower net prices.
- Product differentiation: Demonstrating superior efficacy or safety can sustain premium pricing.
Given these dynamics:
- 2023–2024: Stable at around $180–$210/week.
- 2025–2027: Potential reduction to $150–$180/week as competition intensifies and market penetration increases.
- Post-2027: Further price stabilization or modest declines, aligned with standard market trends and reimbursement policies.
Forecasting Market Penetration & Revenue
Assuming Tlando captures 10–15% of the testosterone gel market by 2027, with a conservative average price of $165/week, the following revenue estimates are plausible:
| Year | Market Share | Estimated Annual Revenue (USD) | Notes |
|---|---|---|---|
| 2023 | 2% | ~$50 million | Early adoption phase |
| 2024 | 5% | ~$125 million | Increasing physician familiarity |
| 2025 | 10% | ~$250 million | Expanded formulary inclusion |
| 2026 | 12% | ~$300 million | Market consolidation |
| 2027 | 15% | ~$375 million | Steady growth |
Note: These figures are preliminary estimates based on assumed market share and average pricing.
Legal and Regulatory Considerations
Patent protections for Tlando, granted through method-of-use patents and formulation exclusivity, will influence pricing strategies. Generic competitors could challenge pricing after patent expiry, potentially reducing prices by 30–50%.
Regulatory pathways for label expansion, such as pediatric or alternative indications, might open additional revenue streams but could also introduce price pressures.
Key Market Risks and Opportunities
Risks:
- Regulatory delays or approvals for competitors.
- Reimbursement restrictions impacting patient access.
- Market saturation with existing TRT formulations.
- Emergence of novel delivery systems (e.g., injections, patches).
Opportunities:
- Growing prevalence of hypogonadism among aging males.
- Advancements in delivery technology boosting patient compliance.
- International expansion into emerging markets.
- Further clinical data supporting safety and efficacy.
Conclusion
Tlando’s market prospects remain promising, with initial positioning within the established testosterone gel segment. Its pricing is expected to remain competitive, initially hovering around current market averages, with potential adjustments downward as the product matures and competition intensifies.
Proactive engagement with payers, strategic differentiation, and ongoing clinical validation will be pivotal in maintaining favorable pricing and market share. By 2027, Tlando could command annual revenues nearing $375 million if early adoption trends continue, supported by a stable yet competitive price point.
Key Takeaways
- Tlando is positioned as an innovative oromucosal testosterone therapy, with a competitive entry point within a growing TRT market.
- Current pricing aligns with market standards ($180–$210/week), with prospects for gradual reductions driven by competitive pressures and manufacturing efficiencies.
- Market growth hinges on increased awareness, physician adoption, insurance coverage, and clinical data supporting its safety profile.
- Revenue projections indicate potential for significant market penetration, with revenues possibly reaching $375 million annually in five years.
- Ongoing patent protections, regulatory environment, and emerging competitors will shape Tlando’s pricing strategies and market share trajectory.
FAQs
1. How does Tlando differentiate itself from other testosterone therapies?
Tlando’s unique delivery via oromucosal gel provides rapid absorption without the skin contact associated with topical gels, potentially improving safety and patient compliance.
2. What factors could impact Tlando’s pricing in the future?
Market competition, manufacturing costs, payer negotiations, and patent expirations are key determinants influencing future pricing adjustments.
3. How significant is the role of insurance coverage for Tlando’s market success?
Insurance reimbursement is critical; higher coverage facilitates access, influences patient out-of-pocket costs, and can sustain higher pricing levels.
4. Will Tlando replace traditional gels or injections?
While it offers an alternative delivery route, adoption depends on clinical outcomes, physician preference, and patient acceptance. It is unlikely to fully replace existing therapies but will complement the TRT options.
5. What is the export potential of Tlando?
International markets with high prevalence of hypogonadism and favorable regulatory landscapes present opportunities for expansion, subject to regulatory approval and pricing negotiations.
References
[1] Market Research Future, “Global Testosterone Replacement Therapy Market,” 2022.
More… ↓
